< >

HyperAcute Immunotherapy

NewLink Genetics has multiple HyperAcute immunotherapies currently under development in a variety of tumors

Phase 3 Trial in Pancreatic Cancer

Now enrolling patients with borderline resectable or locally advanced unresectable pancreatic cancer

Phase 2b/3 Trial in Lung Cancer

Now enrolling patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Investor Relations

Keep up with the latest news and presentations
NewLink Genetics to Present at the Jefferies Global Healthcare Conference
May 29, 2015

NewLink Genetics to Present Poster on Indoximod, an IDO Pathway Inhibitor, at American Society of Clinical Oncology (ASCO) Annual Meeting
May 26, 2015